ReviewJournal of atherosclerosis and thrombosis2019
Diagnosis and Management of Statin Intolerance.
Review in Journal of atherosclerosis and thrombosis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients: a Randomized Crossover Trial
Cholesterol Self-testing in Patients Post Acute Coronary Syndrome
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.
- Statin intolerance management: a systematic review.Endocrine · 2023Pooled it
- Trial
- Trial
- Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial.Circulation. Genomic and precision medicine · 2022Trial
- Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial.Journal of atherosclerosis and thrombosis · 2020Trial
- Structure-guided design of a PCSK9 epitope vaccine with efficacy against hyperlipidemia and atherosclerosis.Life metabolism · 2026Article
- Rational Design and Efficacy Evaluation of a Novel Solid Dispersion-Based Bempedoic Acid-Ezetimibe Fixed-Dose Combination Tablet Versus NexlizetPharmaceutics · 2026Article
- Risk of Hematuria, Proteinuria, and Cardiovascular Events in Patients Treated with Rosuvastatin Compared with Atorvastatin: A Retrospective Cohort Study in 136,680 Patients.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Article
- Protective effects of gypenosides on LDL-induced myocardial injury through the miR-223/NLRP3 axis in hyperlipidemia.Frontiers in nutrition · 2026Article
- Long-Term Safety and Management of Adverse Events Associated With Lorlatinib inJournal of the advanced practitioner in oncology · 2025Article
- Reshaping Dyslipidaemia Treatment with Bempedoic Acid-A Narrative Review.Biomedicines · 2025Review
- The protective effect of coadministration of coenzyme Q10 and vitamin E on myopathy induced by simvastatin in rats.Toxicology reports · 2025Article
- Assessing LDL-C Levels and Lipid-Modifying Therapies in a Real-World Cohort of Patients with Atherosclerotic Cardiovascular Disease: The REALITY Study.Journal of clinical medicine · 2025Article
- Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women.Current atherosclerosis reports · 2025Review
- Review
- Drug-Induced Myopathies: A Comprehensive Review and Update.Biomedicines · 2024Review
- Oxidative Stress-Induced Adverse Effects of Three Statins Following Single or Repetitive Treatments in Mice.Cureus · 2024Article
- Dyslipidaemia as a target for atherosclerotic cardiovascular disease prevention in children with type 1 diabetes: lessons learned from familial hypercholesterolaemia.Diabetologia · 2024Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statins are the main treatment for hypercholesterolemia and the cornerstone of atherosclerotic cardiovascular disease prevention. Many patients taking statins report muscle-related symptoms, one of the most important causes of statin treatment discontinuation, which is associated with an increased risk of cardiovascular events. Therefore, it is important to identify patients who are truly statin intolerant to avoid unnecessary discontinuation of this beneficial treatment. Some studies indicate that not all muscle complaints are caused by statins, and most patients can tolerate a statin upon re-challenge, down-titration of dose, or switching to another statin. In this paper, we review the definitions of statin intolerance and approaches to reducing cardiovascular risk among individuals reporting statin-associated muscle symptoms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.